Cargando…
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
BACKGROUND: Myocarditis is a dreaded and unpredictable complication of immune checkpoint inhibitors (ICI). We sought to determine whether routinely measured biomarkers could be helpful in monitoring for ICI myocarditis. OBJECTIVES: The authors examined biomarker trends of patients on ICI and their a...
Autores principales: | Vasbinder, Alexi, Chen, YeeAnn, Procureur, Adrien, Gradone, Allison, Azam, Tariq U., Perry, Daniel, Shadid, Husam, Anderson, Elizabeth, Catalan, Tonimarie, Blakely, Pennelope, Nelapudi, Namratha, Fardous, Mohamad, Bretagne, Marie C., Adie, Sarah K., Pogue, Kristen T., Leja, Monika, Yentz, Sarah, Schneider, Bryan, Fecher, Leslie A., Lao, Christopher D., Salem, Joe-Elie, Hayek, Salim S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830199/ https://www.ncbi.nlm.nih.gov/pubmed/36636441 http://dx.doi.org/10.1016/j.jaccao.2022.11.004 |
Ejemplares similares
-
Metastatic melanoma of the heart: Retrospective cohort study and systematic review of prevalence, clinical characteristics, and outcomes
por: Balinski, Alexander M., et al.
Publicado: (2022) -
Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019
por: O'Hayer, Patrick J, et al.
Publicado: (2023) -
Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
por: Homan, Morgan, et al.
Publicado: (2022) -
Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021) -
Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)